摘要
目的观察通心宝冲剂对急性冠状动脉综合征(acutecoronarysyndrome,ACS)患者临床疗效及对8-异前列腺素F2a(8-ISO-PGF2a)和血清可溶性CD40L(sCD40L)含量的影响。方法83例ACS患者随机分为通心宝治疗组(42例)和常规治疗组(41例),两组均予常规治疗,通心宝治疗组每天加用通心宝颗粒冲剂1剂(135g),一日一粒,疗程28天.采用ELISA法和酶联免疫吸附法检测两组治疗前后8-ISO-PGF2a及sCD40L的水平.结果通心宝治疗组的治疗后心功能改善明显好于对照组(P<0.01),且死亡率和并发症也低于对照组(P<0.01),两组治疗后8-ISO-PGF2a,sCD40L的水平显著下降(P<0.01),通心宝治疗组8-ISO-PGF2a下降较常规治疗组更明显(P<0.05).结论通心宝冲剂治疗ACS可能与其下调8-ISO-PGF2a的表达,稳定动脉粥样硬化斑块,减轻细胞因子所介导的冠状动脉免疫应答及炎性损伤有关.
Objective To investigate the clinical effect of Tongxinbao pill on plasma concentration of 8-iso-prostaglandinF2a and sCD40L in serum of patients with acute coronary syndrome（ACS）.Methods Eighty-three patients with ACS were randomly divided into the treated group（n=42） and the control group （n=41）.Conventional treatment was given to both groups, and one Tongxinbao pill （135g/d were） given additionally to the treated group, the treatment course for both groups was 28 days. The plasma concentration of 8-iso-prostaglandinF2a and sCD40L in patients Lasted for before and after treatment were determined with ELISA method and enzymelinked immunosorbent assay （ELA） respectively. Results The total curative effect in the treated group were significantly higher than that in the control group （P〈0.01）.The plasma levels of 8-ISO-PGF2a and sCD40L in ACS patients were significant lower than before treatment after treatment （P〈0. 01）,the reduction in the treatment group was more significant than that in the control group （P〈0.05）.Conclusion The effect of Tongxinbao pill on ACS patients may relate to its action in down-regulating the expression of 8-ISO-PGF2a, alleviating the immune reponse and inflammatory injury of coronary system induced by cytokines.
出处
《国际医药卫生导报》
2006年第20期4-6,共3页
International Medicine and Health Guidance News
基金
广东省中医药管理局资助课题(No.20030256)
